← Edwards Lifesciences overview

Edwards Lifesciences vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Edwards Lifesciences Corp (EW)

Q3 2026
▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

  • Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.

    This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.

  • Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.

    This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.

  • TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.

    This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.

  • $10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.

    This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

August 2026
▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

  • Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.

    This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.

  • Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.

    This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.

  • TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.

    This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.

  • $10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.

    This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Latest
▲3▼1

Edwards Lifesciences: Strong TAVR Growth, CMS Coverage Expansion, and TMTT Ambitions

  • Q2 2026 Sales Growth and Raised Guidance Edwards reported Q2 2026 sales of $1.74 billion, up 12.5% year-over-year, with TAVR sales up 10.5% and TMTT up 44.8%. Management raised full-year 2026 sales growth guidance for TAVR, TMTT, and total company, signaling confidence in continued momentum. This strong performance and upbeat outlook push EW's price up as investors see accelerating growth.

    This is a key new event that directly shows the company's financial health and future prospects, driving positive sentiment.

  • Updated CMS Coverage Decision for TAVR CMS updated its national coverage determination to ease patient access to TAVR, removing the coverage with evidence development requirement for symptomatic severe aortic stenosis and expanding coverage to asymptomatic severe cases. This regulatory change could enable 100-200 additional U.S. centers to perform TAVR, boosting demand for Edwards' core product and lifting EW's price.

    This is a new regulatory catalyst that expands the addressable market for Edwards' main product, directly impacting future revenue.

  • TMTT Growth Plan Targeting $2 Billion by 2030 Edwards outlined a plan to exceed $2 billion in transcatheter mitral and tricuspid revenue by 2030, anchored by PASCAL, EVOQUE, and Sapien M3. This long-term growth initiative, combined with the CMS coverage expansion, reinforces the company's transcatheter ecosystem and supports a higher valuation, pushing EW's price up.

    This new strategic target provides a clear long-term growth driver, enhancing investor confidence in future earnings.

  • $10 Million Penalty for Antitrust Violations Edwards must pay a $10 million penalty for antitrust violations related to its JC Medical acquisition, structuring payments to avoid mandatory antitrust review. The company must also establish a compliance program. This regulatory penalty creates a financial and reputational hit, weighing on EW's price.

    This is a new negative event that introduces legal and financial risks, potentially dampening investor enthusiasm.

Integer Holdings Corp (ITGR)

Q3 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

July 2026
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

Latest
▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

  • KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.

    This is the single new event that now sets ITGR's price, so it is the core answer.

  • No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.

    Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.

  • Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.

    Gives the honest counterweight: upside is limited and tied to completion, not to the business.

  • Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.

    It is the only negative force this period, but the buyout has largely overtaken it.

© 2026 MarketIVWhy